uBiome is the leading microbial genomics company.
We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.
Since 2012, we’ve partnered with leading researchers and organizations around the world that are involved in groundbreaking work in microbial genomics.
Recent partnerships have included:
Large-scale study of hospital patients to determine predisposing factors in the microbiome for Hospital-Acquired Infections (HAIs) and develop Microbiome Disruption Indices (MDIs).
Large-scale study of the relationship between genomic and microbiome data in collaboration with PI Dr. George Church.
Examination of the effects of chronic oral antibiotic use on the gut microbiome in acne and rosacea patients as part of our Microbiome Impact Fund program.
Large-scale study of the oral microbiome (in particular, the gingival sulcus) and its correlation with dental diseases, including dental caries, periodontal disease, and gingivitis with PI Dr. Jeremy Horst, DDS.
Crowdsourced study on the relationship between personality traits and the gut microbiome in the US, UK, and selected other countries with PI Dr. Katerina Johnson.
Large-scale study of obesity and the microbiome in children, their parents and siblings with a large variety of diets.
Our mission is to explore important research questions about the microbiome and to develop reliable, precision products and services focused on the microbiome.
uBiome was founded in 2012 by Stanford-, Oxford-, and UCSF-educated researchers.
Our Scientific Advisory Board includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Jonathan Eisen (leading microbiologist at UC Davis), Dr. George Church (leading geneticist at Harvard University), and many other leading scientists.
uBiome is funded by Y Combinator, Andreessen Horowitz, and other leading investors.
uBiome has been the recipient of numerous awards, including the Top 10 Most Innovative Companies in Healthcare (Fast Company), Top Prize at the IVY Awards, and CNN 10: Startups To Watch.
The human microbiome has a profound impact on our health. It has been correlated with a wide range of conditions, including obesity and Type 2 diabetes, as well as Inflammatory Bowel Disease (IBD) and irritable bowel syndrome (IBS).
uBiome’s mission is to explore important research questions about the microbiome and develop accurate and reliable clinical tests based on the microbiome.